PARP Inhibitor Biomarkers Market, By Product (Kits, Assays), Service (BRCA 1 & 2 Testing, HRD Testing, HRR Testing), Application (Breast Cancer, Ovarian Cancer), End-use (Hospitals & Clinics, Diagnostic Laboratories) – Global Forecast (2024 – 2032)

PARP Inhibitor Biomarkers Market Size

PARP Inhibitor Biomarkers Market was valued at around USD 905.3 million in 2023 and is estimated to grow at 8.3% CAGR from 2024 to 2032. PARP inhibitor biomarkers refer to specific biological indicators used to predict or assess the effectiveness of PARP (Poly ADP-Ribose Polymerase) inhibitors in cancer treatment. These biomarkers are typically genetic or molecular characteristics present in tumor cells that influence the response to PARP inhibitors. They play a crucial role in precision medicine by helping oncologists identify patients who are most likely to benefit from PARP inhibitor therapy and tailor treatment plans accordingly.
 

Breast cancer is one of the most common types of cancer globally, and its prevalence has been steadily increasing over the years. For instance, breast cancer claims 670,000 lives worldwide annually, as reported by the World Health Organization (WHO) in 2022. Nearly half of all breast cancer diagnoses are found in women without identifiable risk factors beyond gender and age. In 2022, breast cancer ranked as the most prevalent form of cancer among women in 157 out of 185 countries. Its incidence spans across every nation globally. Approximately 0.5–1% of breast cancer cases manifest in men. This rise in prevalence necessitates more effective treatment options. PARP inhibitors have shown promise in the treatment of breast cancer, particularly in patients with BRCA mutations. Therefore, as the number of breast cancer cases rises, there is a greater demand for targeted therapies like PARP inhibitors, thereby propelling the growth of the market.
 

Further, personalized medicine in oncology which is estimated to reach USD 690 billion by 2032, customizes treatments based on the unique characteristics of each patient. PARP inhibitors, which focus on specific molecular pathways in cancer development, showcase this strategy. Biomarker testing assists clinicians in pinpointing the patients best suited for PARP inhibitor therapy, thus improving effectiveness while reducing side effects.
 

PARP Inhibitor Biomarkers Market Trends

Genomic technologies, including next-generation sequencing (NGS) and gene expression profiling, have transformed cancer research and treatment. These methods allow for the detection of precise genetic mutations and alterations that propel cancer advancement. For PARP inhibitors, genomic testing can pinpoint patients harbouring mutations in DNA repair pathways, like BRCA1 and BRCA2, enhancing the likelihood of response to PARP inhibitor therapy.
 

• With increasing healthcare expenditure dedicated to cancer treatment, there is a growing emphasis on therapies that offer improved efficacy and fewer adverse effects.
   
• PARP inhibitors represent a novel approach to cancer treatment, and investments in research and development have expanded the understanding of their mechanisms of action and potential biomarkers for patient stratification, propelling the market growth.
   

PARP Inhibitor Biomarkers Market Analysis

Based on product, the market is divided into kits and assays. The kits segment of the PARP inhibitor biomarkers industry is forecasted to reach USD 1.1 million by 2032, showcasing robust growth propelled by several key factors.
 

• The increasing prevalence of cancer, particularly breast and ovarian cancers, has heightened the demand for effective treatment options such as PARP inhibitors. As these inhibitors gain prominence in oncology, the need for reliable biomarker kits to assess patient suitability for PARP inhibitor therapy grows significantly.
   
• Furthermore, the rising adoption of companion diagnostics, which are integral for determining patient eligibility for specific targeted therapies like PARP inhibitors, contributes to the increasing demand for biomarker kits.
   
• The FDA-approved myChoice CDx test from Myriad Genetics, Inc., is designed to identify patients with advanced ovarian cancer demonstrating positive homologous recombination deficiency (HRD) status. Healthcare providers and pharmaceutical companies alike recognize the value of companion diagnostics in guiding treatment decisions, thus stimulating the uptake of biomarker kits in clinical practice.

Based on service, the PARP inhibitor biomarkers market is bifurcated into BRCA 1 & 2 testing, HRD testing, HRR testing, and other services. The BRCA 1 & 2 testing segment accounted for USD 374.1 million in 2023.
 

• This surge can be attributed to the segment's critical role in identifying individuals at risk of hereditary breast and ovarian cancers, bolstered by growing awareness among healthcare providers and patients.
   
• The therapeutic implications of BRCA mutations, particularly in guiding treatment decisions with PARP inhibitor therapies, further fueled the demand for accurate testing services.
   
• Expanded testing guidelines, technological advancements, and supportive reimbursement policies have also contributed to the segment's remarkable performance.
   

Based on application, the PARP inhibitor biomarkers industry is bifurcated into breast cancer, ovarian cancer, and other applications. The breast cancer segment accounted for USD 409.3 million in 2023.
 

• Heightened global awareness and increased screening efforts for breast cancer have driven demand for advanced treatments like PARP inhibitors.
   
• Significant advancements in medical research have revealed the effectiveness of PARP inhibitors in targeting specific genetic mutations associated with breast cancer, leading to their widespread adoption.
   
• Moreover, the approval and commercialization of tailored PARP inhibitor drugs for breast cancer, along with supportive regulatory environments and reimbursement policies, have further fueled market growth.
   
• These factors collectively underscore the commanding position of the breast cancer segment within the market.
   

Based on end-use, the PARP inhibitor biomarkers market is bifurcated into hospitals and clinics, diagnostic laboratories, academic and research institutes, and other end-users. The hospitals and clinics segment accounted for USD 387.4 million in 2023.
 

• This prominence is primarily driven by the high clinical demand within these facilities, which serve as key points of care for patients requiring diagnosis and treatment, particularly in oncology.
   
• The presence of specialized oncology departments equipped with advanced diagnostic technologies and the preference of healthcare professionals for personalized treatment strategies further bolster this segment's significance.
   
• Additionally, hospitals and clinics possess the necessary infrastructure, resources, and established protocols for efficient biomarker testing. Patient accessibility, coupled with favorable reimbursement policies, also contribute to the segment's substantial market share.
   
• Therefore, the hospitals and clinics segment play a pivotal role in facilitating biomarker testing and subsequent treatment decisions in diseases targeted by PARP inhibitors.

The PARP inhibitor biomarkers industry in North America accounted for a significant revenue of USD 369.4 million in 2023, and this trajectory is set to continue upwards.
 

• The growing occurrence of cancer in the region, particularly breast and ovarian cancers, which are key focuses for PARP inhibitors, underscores the importance of precise biomarker testing to guide treatment decisions. According to the Centers for Disease Control and Prevention (CDC), annually in the U.S., approximately 240,000 instances of breast cancer are identified among women and around 2,100 among men. Breast cancer claims the lives of about 42,000 women and 500 men in the U.S. each year.
   
• Thus, with the growing prevalence of cancer, more patients are turning to genetic testing to pinpoint candidates for PARP inhibitor therapy, leading to a surge in demand for biomarker testing.
   

UK is anticipated to witness robust growth in the global market.
 

• The UK boasts a strong biomedical research infrastructure, including renowned universities, hospitals, and research institutes.
   
• Clinical trials investigating the efficacy and safety of PARP inhibitors are ongoing in the UK, contributing to the growing body of evidence supporting their use in cancer treatment. This research activity not only enhances clinical understanding but also drives the adoption of biomarker testing in clinical practice.
   

Japan market is anticipated to witness lucrative growth between 2024 – 2032.
 

• The convergence of next-generation sequencing (NGS) and liquid biopsy technologies in Japan's healthcare landscape is driving a paradigm shift towards precision oncology, with implications for the PARP inhibitor biomarkers industry.
   
• These advancements not only enable the identification of novel biomarkers associated with PARP inhibitor response but also improve patient access to personalized treatment options.
   

South Korea PARP inhibitor biomarkers market is expected to grow significantly over the years.
 

• South Korea is witnessing an escalation in cancer incidence rates. PARP inhibitors demonstrate effectiveness in treating diverse cancers such as breast, ovarian, and prostate cancers. Estimated figures indicate that in 2020, South Korea documented around 24.9 thousand cases of breast cancer, affirming its position as one of the prevalent cancer types.
   
• With the ongoing surge in these cancer types, there arises a pressing need for cancer biomarkers capable of accurately identifying patients poised to gain the most from PARP inhibitor therapy.
   

The PARP inhibitor biomarkers industry in Saudi Arabia is expected to experience significant and promising growth from 2024 to 2032.
 

• The pharmaceutical industry in Saudi Arabia is expanding, with more companies entering the market and investing in research and development. This will lead to the development of new PARP inhibitors and companion diagnostic tests, further driving growth in the biomarkers testing market.
   

PARP Inhibitor Biomarkers Market Share

The PARP inhibitor biomarkers sector is competitive in nature, with a mix of major global and smaller to medium-sized companies competing for market share. A pivotal aspect of market strategy involves the continual introduction of innovative products leveraging diverse technologies. Notably, prominent industry players command significant influence in this dynamic landscape, often driving forward advancements through substantial investments in research and development. Additionally, strategic alliances, acquisitions, and mergers are instrumental in fortifying market positions and expanding global footprint amidst evolving regulatory landscapes.
 

PARP Inhibitor Biomarkers Market Companies

Some of the eminent market participants operating in the PARP inhibitor biomarkers industry include:

• Agilent Technologies, Inc.
• Ambry Genetics
• Amoy Diagnostics Co., Ltd.
• Centogene N.V
• Illumina, Inc.
• Invitae Corporation
• Myriad Genetics, Inc.
• Neogenomics, Inc.
• QIAGEN N.V.
• Thermo Fisher Scientific Inc.
   

PARP Inhibitor Biomarkers Industry News

• In January 2024, Myriad Genetics, Inc., a prominent figure in genetic testing and precision medicine, finalized an agreement to acquire specific assets from Intermountain Precision Genomics’ (IPG) laboratory division. These assets included the Precise Tumor Test, the Precise Liquid Test, and IPG’s CLIA-certified laboratory located in St. George, Utah. This strategic acquisition is expected to bolster Myriad Genetics' market presence in genetic testing and precision medicine, positioning the company competitively within the industry.
   

The PARP inhibitor biomarkers market research report includes an in-depth coverage of the industry with estimates & forecast in terms of revenue in USD Million from 2021 – 2032 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Kits
• Assays

Market, By Service

• BRCA (Breast cancer gene) 1 & 2 testing
• HRD (Homologous recombination deficiency) testing
• HRR (Homologous recombination repair) testing
• Other services

Market, By Application

• Breast cancer
• Ovarian cancer
• Other applications 

Market, By End-use

• Hospitals and clinics
• Diagnostic laboratories
• Academic and research institutes
• Other end-users

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada 
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
  • Rest of Europe 
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia Pacific 
• Latin America 
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America 
• Middle East and Africa 
  • Saudi Arabia
  • South Africa
  • UAE
  • Rest of Middle East and Africa